Gene therapy progress and prospects: The skin - Easily accessible, but still far away

Gene Therapy

Volumn 13, Issue 22, 2006, Pages 1555-1563

  Hengge, U R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER 12; ALPHA5 INTEGRIN; BETA DEFENSIN 3; CATHELICIDIN; COLLAGEN TYPE 7; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DESMIN; DNA VACCINE; INTEGRASE; INTERLEUKIN 12; KERATIN; KERATINOCYTE GROWTH FACTOR; LIPOSOME; MONOPHENOL MONOOXYGENASE; NAKED DNA; NUCLEASE; PLASMID DNA; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE INHIBITOR; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VASCULOTROPIN; ZINC FINGER PROTEIN;

ADENOVIRUS VECTOR; BACTERIOPHAGE; CANARYPOX VIRUS; CELL BASED GENE THERAPY; CLINICAL TRIAL; CONGENITAL SKIN DISEASE; DNA REPAIR; DNA VECTOR; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG UPTAKE; EPIDERMIS; EPIDERMOLYSIS BULLOSA; EX VIVO STUDY; FLU LIKE SYNDROME; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC CODE; GENETIC ENGINEERING; GENODERMATOSIS; HUMAN; ICHTHYOSIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INJECTION SITE REACTION; KERATINOCYTE; LENTIVIRUS VECTOR; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARVOVIRUS VECTOR; PLASMID VECTOR; PRIORITY JOURNAL; RETROVIRUS VECTOR; REVIEW; RNA INTERFERENCE; SKIN FIBROBLAST; SKIN GRAFT; STEM CELL TRANSPLANTATION; TRANSPOSON; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WOUND;

ANIMALS; DNA; FORECASTING; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, ANIMAL; SKIN; SKIN ABSORPTION; SKIN DISEASES; VACCINES, DNA;

ANIMALIA;

EID: 33750616005     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302855     Document Type: Review

References (51)

1. Uitto J, Richard G. Progress in epidermolysis bullosa: Genetic classification and clinical implications. Am J Med Genet C 2004; 131: 61-74.
2. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 2003; 111: 251-255.
3. Hengge UR, Bardenheuer W. Gene therapy and the skin. Am J Med Genet C 2004; 131: 93-100.
4. Gagnoux-Palacios L, Hervouet C, Spirito F, Roques S, Mezzina M, Danos O et al. Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J Gene Med 2005; 7: 1178-1186.
5. Serrano F, Del Rio M, Larcher F, Garcia M, Munoz E, Escamez MJ et al. A comparison of targeting performance of oncoretroviral versus lentiviral vectors on human keratinocytes. Hum Gene Ther 2003; 14: 1579-1585.
6. Bajaj BG, Lei P, Andreadis ST. Efficient gene transfer to human epidermal keratinocytes on fibronectin: In vitro evidence for transduction of epidermal stem cells. Mol Ther 2005; 11: 969-979.
7. Braun-Falco M, Eisenried A, Buning H, Ring J. Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase. Arch Dermatol Res 2005; 296: 528-535.
8. Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S et al. Evaluation of tumor-specific promoter activities in melanoma. Gene Therapy 2005; 12: 330-338.
9. Okada Y, Okada N, Mizuguchi H, Hayakawa T, Nakagawa S, Mayumi T. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Ther 2005; 12: 608-616.
10. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Therapy 2003; 10: 1099-1104.
11. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther 2003; 14: 923-928.
12. Laposa RR, Feeney L, Cleaver JE. Recapitulation of the cellular xeroderma pigmentosum-variant phenotypes using short interfering for DNA polymerase H. Cancer Res 2003; 63: 3909-3912.
13. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646-651.
14. D'Alessandro M, Morley SM, Ogden PH, Liovic M, Porter RM, Lane EB. Functional improvement of mutant keratin cells on addition of desmin: An alternative approach to gene therapy for dominant diseases. Gene Therapy 2004; 11: 1290-1295.
15. Arin MJ, Roop DR. Inducible mouse models for inherited skin diseases: implications for skin gene therapy. Cells Tissues Organs 2004; 177: 160-168.
16. Baldeschi C, Gache Y, Rattenholl A, Bouille P, Danos O, Ortonne JP et al. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet 2003; 12: 1897-1905.
17. Gache Y, Baldeschi C, Del Rio M, Gagnoux-Palacios L, Larcher F, Lacour JP, Meneguzzi G. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 2004; 15: 921-933.
18. Woodley DT, Keene DR, Atha T, Huang Y, Ram R, Kasahara N et al. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 2004; 10: 318-326.
19. Marchetto MC, Muotri AR, Burns DK, Friedberg EC, Menck CF. Gene transduction in skin cells: Preventing cancer in xeroderma pigmentosum mice. Proc Natl Acad Sci USA 2004; 101: 17759-17764.
20. Zhang F, Yang F, Hu EC, Sones W, Lei M, Lineaweaver WC. Vascular endothelial growth factor gene therapy in improvement of skin paddle survival in a rat TRAM flap model. J Reconstr Microsurg 2005; 21: 391-396.
21. Carretero M, Del Rio M, Garcia M, Escamez MJ, Mirones I, Rivas L et al. A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. FASEB J 2004; 18: 1931-1933.
22. Jacobsen F, Mittler D, Hirsch T, Gerhards A, Lehnhardt M, Voss B et al. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Therapy 2005; 12: 1494-1502.
23. Sawamura D, Goto M, Shibaki A, Akiyama M, McMillan JR, Abiko Y et al. Beta defensin-3 engineered epidermis shows highly protective effect for bacterial infection. Gene Therapy 2005; 12: 857-861.
24. Marti G, Ferguson M, Wang J, Byrnes C, Dieb R, Qaiser R et al. Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model. Gene Therapy 2004; 11: 1780-1785.
25. Lee PY, Chesnoy S, Huang L. Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol 2004; 123: 791-798.
26. Liu W, Chua C, Wu X, Wang D, Ying D, Cui L et al. Inhibiting scar formation in rat wounds by adenovirus-mediated overexpression of truncated TGF-beta receptor II. Plast Reconstr Surg 2005; 115: 860-870.
27. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest 2005; 115: 1777-1784.
28. Lee H, Koehler DR, Pang CY, Levine RH, Ng P, Palmer DJ et al. Gene delivery to human sweat glands: A model for cystic fibrosis gene therapy. Gene Therapy 2005; 12: 1752-1760.
29. Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy. Hum Gene Ther 2005; 16: 35-48.
30. Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE et al. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 2005; 16: 91-100.
31. Moiseyenko VM, Danilov AO, Baldueva IA, Danilova AB, Tyukavina NV, Larin SS et al. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: Miscellaneous tumors. Ann Oncol 2005; 16: 162-168.
32. Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 2005; 54: 453-467.
33. Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K et al. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 2004; 172: 1304-1310.
34. Ghazizadeh S, Kalish RS, Taichman LB. Immune-mediated loss of transgene expression in skin: Implications for cutaneous gene therapy. Mol Ther 2003; 7: 296-303.
35. Lu Z, Ghazizadeh S. Host immune responses in ex vivo approaches to cutaneous gene therapy targeted to keratinocytes. Exp Dermatol 2005; 14: 727-735.
36. Ohyama M, Ota T, Aoki M, Tsunoda K, Harada R, Koyasu S et al. Suppression of the immune response against exogenous desmoglein 3 in desmoglein 3 knockout mice: An implication for gene therapy. J Invest Dermatol 2003; 120: 610-615.
37. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-1356.
38. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63: 8408-8413.
39. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O,Wang L et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 2004; 104: 969-977.
40. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004; 22: 1700-1708.
41. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005; 7: 3-17.
42. Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N et al. Derma Vir: A novel topical vaccine for HIV/AIDS. J Invest Dermatol 2005; 124: 160-169.
43. Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 2005; 20: 1-12; (E-pub ahead of print).
44. Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol 2004; 172: 5561-5569.
45. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9: 729-735.
46. Bramson J, Dayball K, Evelegh C, Wan YH, Page D, Smith A. Enabling topical immunization via microporation: A novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Therapy 2003; 10: 251-260.
47. Dayball K, Millar J, Miller M, Wan YH, Bramson J. Electroporation enables plasmid vaccines to elicit CD8+ T cell responses in the absence of CD4+ T cells. J Immunol 2003; 171: 3379-3384.
48. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clin Cancer Res 2003; 9: 1284-1290.
49. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005; 54: 3-20.
50. Meykadeh N, Mirmohammadsadegh A, Wang Z, Basner-Tschakarjan E, Hengge UR. Topical application of plasmid DNA to mouse and human skin. J Mol Med 2005; 83: 897-903.
51. Basner-Tschakarjan E, Mirmohammadsadegh A, Baer A, Hengge UR. Uptake and trafficking of DNA in keratinocytes: Evidence for DNA-binding proteins. Gene Therapy 2004; 11: 765-774.